Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. Chief Accounting Officer Joseph Ronald Catapano reported the vesting of restricted stock units and a related share sale. On July 1, 2026, 2,083 restricted stock units converted into the same number of common shares at a conversion price of $0.00 per share. According to the footnotes, these units convert to Teladoc common stock on a one-for-one basis and relate to a 25,000-unit grant awarded on October 1, 2024.
On July 2, 2026, 653 common shares were sold at $9.10 per share. A footnote explains that these shares were sold to cover the tax withholding obligation arising from the RSU vesting, indicating a compensation-related, non-discretionary sale rather than an ordinary portfolio transaction. Following these transactions, Catapano directly holds 12,267 Teladoc common shares, and 10,418 restricted stock units remain outstanding.
TDOC filing a Form 144 notice for proposed resale of 2,500 shares of Common Stock pursuant to restricted stock vesting on 03/19/2025. The filing also discloses recent open-market sales by Kelly M. Bliss of 7,679, 2,500, and 2,500 shares on 06/02/2026, 06/29/2026, and 07/01/2026, with dollar amounts reported alongside each sale.
Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock in an open-market transaction at $9.00 per share, totaling $22,500. After the sale, she directly holds 87,378 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
TDOC filed Form 144 reporting sales and recent restricted‑stock vesting for Common stock. The filing lists restricted stock vesting of 118 shares on 03/19/2025 and 2,382 shares on 06/01/2025. It also reports sales of 7,679 shares for $58,567.73 on 06/02/2026 and 2,500 shares for $21,250.00 on 06/29/2026.
Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, reported an open-market sale of common stock. On June 29, 2026, she sold 2,500 shares of Teladoc Health common stock at $8.50 per share.
The filing states that this transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025, indicating it was pre-arranged rather than timed discretionarily. After this sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.
Teladoc Health affiliate files a Form 144 proposing resale of securities. The notice lists 2,500 shares tied to Restricted Stock Vesting with a 06/01/2025 vesting date and records 7,679 shares sold in the prior three months for $58,567.73. The broker listed is Fidelity Brokerage Services LLC.
Teladoc Health (Common Stock) ownership disclosure: a group led by Voss entities and Travis W. Cocke reports beneficial ownership stakes in the issuer. The filing lists specific holdings by entity, including 9,025,722 shares held by Voss Capital/Cocke-affiliated accounts and related entities and references 180,513,087 shares outstanding as of April 23, 2026.
The schedule states that Voss Value Master Fund beneficially owns 1,803,606 shares (including 700,000 shares underlying currently exercisable call options), Voss Value-Oriented Special Situations Fund owns 200,000 shares, and Voss GP may be deemed to beneficially own both fund holdings. The filing attributes approximately 5.00% beneficial ownership to Voss Capital and to Travis W. Cocke on an aggregate basis, and smaller percentages to the other named reporting persons.
Teladoc Health, Inc. CEO Charles DiVita III reported a mix of equity compensation activity and related share sales. On June 10, 2026, he exercised restricted stock units and performance stock units that convert one-for-one into common shares, receiving 39,160 and 3,642 shares of common stock, respectively.
On June 11, 2026, he sold 18,074 shares of common stock at $6.942 per share. A footnote states these shares were sold to cover the tax withholding obligation from the vesting of his performance and restricted stock unit awards, rather than as a discretionary open-market sale for liquidity.
After these transactions, DiVita directly holds 414,622 shares of Teladoc common stock. Footnotes also note he earned 23,591 performance stock units on June 10, 2026, scheduled to vest partially on March 10, 2026 with the remainder in five quarterly installments, and that a prior grant of 469,924 restricted stock units from June 10, 2024 continues to vest over time.
Fidelity Brokerage Services LLC submitted a Form 144 notice relating to 18,074 shares of Common Stock proposed for sale following a Restricted Stock Vesting event on 06/10/2026. The filing records the shares as compensation issued by the Issuer.
Separately, the excerpt shows prior sales by Charles Divita of 27,731 shares on 03/11/2026 and 19,132 shares on 06/02/2026, with dollar amounts noted in the table.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported an open-market sale of 9,572 shares of common stock at $7.40 per share. Following this transaction, his directly held common stock position in this account was reduced to 0 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 3, 2025, indicating the trades were scheduled in advance.